NASDAQ Framework: TG Therapeutics Inc.
Biopharmaceutical company focused on B-cell diseases 1.
1: TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. View Source
TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company that focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company offers BRIUMVI, an anti-CD20 monoclonal antibody, for treating adult patients with relapsing forms of multiple sclerosis (RMS). TG Therapeutics' development pipeline includes Umbralisib, an oral PI3K-delta inhibitor for relapsed or refractory marginal zone lymphoma and follicular lymphoma, TG-1701, a BTK inhibitor, and TG-1801, a bispecific CD47 and CD19 antibody. The company is also engaged in various research collaborations and license agreements to advance its investigational medicines 23.
2: TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. View Source3: TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting... View Source
4: Investor's Business Daily•12 days agoHealth Care Stocks Give IBD 50 A Boost, And These Are Making Bullish MovesThursday's stock market shake-up didn't change the IBD 50 much, and some sectors are solidifying their leadership. Seven of the 50 stocks in Friday's list were biotechs — the most of any single industry group. Mirum Pharmaceuticals broke out of a cup base the past week and is extended from the 35.56 buy point.Investor's Business Daily•28 days agoStocks To Watch: Biotech Leader TG Therapeutics Clears Resistance AreaAmong the best stocks to watch, biotech leader TG Therapeutics is clearing a key resistance area on the stock market today.GuruFocus.com•last monthInsider Sale: Director Sagar Lonial Sells 25,933 Shares of TG Therapeutics Inc (TGTX)On June 20, 2024, Director Sagar Lonial executed a significant transaction by selling 25,933 shares of TG Therapeutics Inc (NASDAQ:TGTX). The shares were sold at a price of $16.69 each, as detailed in the SEC Filing. Following this transaction, the insider now owns 105,195 shares of the company.GlobeNewswire•2 months agoTG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceFireside chat scheduled for Tuesday, June 11, 2024, at 1:20 PM ETNEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, being held at the Loews Miami Beach Hotel, Miami Beach, FL on June 10-13, 2024. The fireside chat is scheduled to take place on Tuesday, June 11, 2024, at 1:20 PM ET. A live webcast oGlobeNewswire•2 months agoTG Therapeutics to Participate in the Jefferies Global Healthcare ConferenceFireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ETNEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 5-6, 2024. The fireside chat is scheduled to take place on Wednesday, June 5, 2024, at 1:30 PM ET. A live webcast of the fireside chat wiGlobeNewswire•2 months agoTG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual MeetingNEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links. Link to Poster Presentation: A Post-Marketing Study Evaluating the Presence anSimply Wall St.•2 months agoDespite shrinking by US$192m in the past week, TG Therapeutics (NASDAQ:TGTX) shareholders are still up 131% over 5 yearsThe worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...GlobeNewswire•2 months agoTG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual MeetingNEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee. Abstracts are now available online and can be accessed on the CMInsider Monkey•3 months agoTG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call TranscriptTG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript May 2, 2024 TG Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the TG Therapeutics Conference Call and Webcast. At this time all participants are […]Simply Wall St.•3 months agoRainbows and Unicorns: TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Became A Lot More OptimisticTG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders will have a reason to smile today, with the analysts making... View Source5: GuruFocus.com•last monthInsider Sale: Director Sagar Lonial Sells 25,933 Shares of TG Therapeutics Inc (TGTX)On June 20, 2024, Director Sagar Lonial executed a significant transaction by selling 25,933 shares of TG Therapeutics Inc (NASDAQ:TGTX). The shares were sold at a price of $16.69 each, as detailed in the SEC Filing. Following this transaction, the insider now owns 105,195 shares of the company.GlobeNewswire•2 months agoTG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceFireside chat scheduled for Tuesday, June 11, 2024, at 1:20 PM ETNEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, being held at the Loews Miami Beach Hotel, Miami Beach, FL on June 10-13, 2024. The fireside chat is scheduled to take place on Tuesday, June 11, 2024, at 1:20 PM ET. A live webcast oGlobeNewswire•2 months agoTG Therapeutics to Participate in the Jefferies Global Healthcare ConferenceFireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ETNEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 5-6, 2024. The fireside chat is scheduled to take place on Wednesday, June 5, 2024, at 1:30 PM ET. A live webcast of the fireside chat wiGlobeNewswire•2 months agoTG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual MeetingNEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links. Link to Poster Presentation: A Post-Marketing Study Evaluating the Presence anSimply Wall St.•2 months agoDespite shrinking by US$192m in the past week, TG Therapeutics (NASDAQ:TGTX) shareholders are still up 131% over 5 yearsThe worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...GlobeNewswire•2 months agoTG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual MeetingNEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee. Abstracts are now available online and can be accessed on the CMInsider Monkey•3 months agoTG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call TranscriptTG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript May 2, 2024 TG Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the TG Therapeutics Conference Call and Webcast. At this time all participants are […]Simply Wall St.•3 months agoRainbows and Unicorns: TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Became A Lot More OptimisticTG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders will have a reason to smile today, with the analysts making...Simply Wall St.•3 months agoTG Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsTG Therapeutics ( NASDAQ:TGTX ) First Quarter 2024 Results Key Financial Results Revenue: US$63.5m (up by US$55.7m from...GuruFocus.com•3 months agoTG Therapeutics Inc (TGTX) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue Growth ...Despite a net loss, TG Therapeutics Inc reports significant revenue increases and strategic advancements in Q1 2024, setting a positive trajectory for the year. View Source6: TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. View Source
MEDIUM RISK
TG Therapeutics Inc. has shown significant revenue growth and positive business developments, such as substantial upgrades to revenue and earnings forecasts 789. However, the company is expected to grow slower than the wider market and other industry participants 10. Additionally, while there is an expectation for the company to become profitable this year, it has a high price-to-earnings ratio and forward price-to-earnings ratio, indicating potential overvaluation 1112. These factors suggest that while the company is on a positive trajectory, there are still inherent risks that prevent it from being classified as low risk.
TG Therapeutics Inc. has shown significant revenue growth and positive business developments, such as substantial upgrades to revenue and earnings forecasts 789. However, the company is expected to grow slower than the wider market and other industry participants 10. Additionally, while there is an expectation for the company to become profitable this year, it has a high price-to-earnings ratio and forward price-to-earnings ratio, indicating potential overvaluation 1112. These factors suggest that while the company is on a positive trajectory, there are still inherent risks that prevent it from being classified as low risk.
7: TG Therapeutics, Inc. (NASDAQ:TGTX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus statutory numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects. TG Therapeutics has also found favour with investors, with the stock up a worthy 18% to US$16.42 over the past week. We'll be curious to see if these new estimates convince the market to lift the stock price higher still. View Source8: The most important thing to take away from this upgrade is that there is now an expectation for TG Therapeutics to become profitable this year, compared to previous expectations of a loss. Pleasantly, analysts also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow slower than the wider market. With a serious upgrade to expectations and a rising price target, it might be time to take another look at TG Therapeutics. View Source9: Following the upgrade, the most recent consensus for TG Therapeutics from its seven analysts is for revenues of US$311m in 2024 which, if met, would be a satisfactory 7.5% increase on its sales over the past 12 months. Statutory earnings per share are anticipated to plummet 72% to US$0.079 in the same period. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$268m and losses of US$0.11 per share in 2024. It looks like there's been a definite improvement in business conditions, with a revenue upgrade supposed to lead to profitability sooner than previously forecast. View Source10: One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that TG Therapeutics' revenue growth will slow down substantially, with revenues to the end of 2024 expected to display 10% growth on an annualised basis. This is compared to a historical growth rate of 95% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 18% per year. Factoring in the forecast slowdown in growth, it seems obvious that TG Therapeutics is also expected to grow slower than other industry participants. View Source11: The stock’s market cap achieved a total value of $3.25 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for TG Therapeutics Inc (NASDAQ:TGTX) is 95.24. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 34.93. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 11.22 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 20.27, which equates the market value of a stock with its book value. View Source12: The stock’s market cap achieved a total value of $3.29 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for TG Therapeutics Inc (NASDAQ:TGTX) is 96.46. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 35.90. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 11.36 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 20.53, which equates the market value of a stock with its book value. View Source
13: TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. View Source14: TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting... View Source15: TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). View Source
TG Therapeutics Inc.'s product roadmap and expansion strategy for 2024 through to 2026 focuses on the continued development and commercialization of their existing and investigational treatments for B-cell mediated diseases. The company is advancing its pipeline, which includes Umbralisib, TG-1701, and TG-1801, alongside its already commercialized product, BRIUMVI, for relapsing forms of multiple sclerosis (RMS) 1617. Additionally, TG Therapeutics is engaged in various research collaborations and license agreements to support the development of these treatments 18. The company has also seen significant upgrades in revenue and earnings forecasts, suggesting a positive business outlook and potential profitability in the near future 1920.
16: TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. View Source17: TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting... View Source18: TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. View Source19: Following the upgrade, the most recent consensus for TG Therapeutics from its seven analysts is for revenues of US$311m in 2024 which, if met, would be a satisfactory 7.5% increase on its sales over the past 12 months. Statutory earnings per share are anticipated to plummet 72% to US$0.079 in the same period. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$268m and losses of US$0.11 per share in 2024. It looks like there's been a definite improvement in business conditions, with a revenue upgrade supposed to lead to profitability sooner than previously forecast. View Source20: It will come as no surprise to learn that the analysts have increased their price target for TG Therapeutics 5.5% to US$31.38 on the back of these upgrades. View Source